Tags

Type your tag names separated by a space and hit enter

Primary liver cancers with nonalcoholic steatohepatitis.
Eur J Gastroenterol Hepatol. 2007 Oct; 19(10):827-34.EJ

Abstract

Nine patients with hepatocellular carcinoma (HCC) in nonalcoholic steatohepatitis (NASH) (six men and three women, median age 71.5 years) and one patient with intrahepatic cholangiocarcinoma (ICC), a 50-year-old man, in NASH are described. Most patients were associated with obesity, diabetes, hypertension, hypercholesterolemia, or hypertriglyceridemia. Seven patients showed insulin resistance and hyperinsulinemia. All patients except one met the criteria for metabolic syndrome. An HCC or ICC diagnosis was confirmed by tumor biopsy, surgery or autopsy except in two patients, who were diagnosed by computed tomography or hepatic angiography. The underlying liver disease was liver cirrhosis in six patients and chronic liver disease including mild hepatic fibrosis in four patients. The treatment of liver cancers consisted of surgery, radio-frequency ablation (RFA), transcatheter arterial embolization and transcatheter arterial infusion. Although the follow-up period was relatively short (median 27.5 months, average 32.1 months), all postoperative and post-RFA patients have not had a recurrence of HCC to date, except for one patient who had a palliative operation with intra-arterial infusion of anticancer drugs through an implanted reservoir port. Older age and liver cirrhosis are considered risk factors for HCC in NASH, and regular screening of these patients is necessary. Diabetes may contribute to the development of ICC in NASH. Curative therapy (surgery or RFA) and weight loss by the active therapeutic intervention (nutritional care and exercise therapy) after curative therapy may help us improve the prognosis of HCC in NASH.

Authors+Show Affiliations

Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Review

Language

eng

PubMed ID

17873605

Citation

Hashizume, Hiroaki, et al. "Primary Liver Cancers With Nonalcoholic Steatohepatitis." European Journal of Gastroenterology & Hepatology, vol. 19, no. 10, 2007, pp. 827-34.
Hashizume H, Sato K, Takagi H, et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2007;19(10):827-34.
Hashizume, H., Sato, K., Takagi, H., Hirokawa, T., Kojima, A., Sohara, N., Kakizaki, S., Mochida, Y., Shimura, T., Sunose, Y., Ohwada, S., & Mori, M. (2007). Primary liver cancers with nonalcoholic steatohepatitis. European Journal of Gastroenterology & Hepatology, 19(10), 827-34.
Hashizume H, et al. Primary Liver Cancers With Nonalcoholic Steatohepatitis. Eur J Gastroenterol Hepatol. 2007;19(10):827-34. PubMed PMID: 17873605.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Primary liver cancers with nonalcoholic steatohepatitis. AU - Hashizume,Hiroaki, AU - Sato,Ken, AU - Takagi,Hitoshi, AU - Hirokawa,Tomoyuki, AU - Kojima,Akira, AU - Sohara,Naondo, AU - Kakizaki,Satoru, AU - Mochida,Yasushi, AU - Shimura,Tatsuo, AU - Sunose,Yutaka, AU - Ohwada,Susumu, AU - Mori,Masatomo, PY - 2007/9/18/pubmed PY - 2008/1/11/medline PY - 2007/9/18/entrez SP - 827 EP - 34 JF - European journal of gastroenterology & hepatology JO - Eur J Gastroenterol Hepatol VL - 19 IS - 10 N2 - Nine patients with hepatocellular carcinoma (HCC) in nonalcoholic steatohepatitis (NASH) (six men and three women, median age 71.5 years) and one patient with intrahepatic cholangiocarcinoma (ICC), a 50-year-old man, in NASH are described. Most patients were associated with obesity, diabetes, hypertension, hypercholesterolemia, or hypertriglyceridemia. Seven patients showed insulin resistance and hyperinsulinemia. All patients except one met the criteria for metabolic syndrome. An HCC or ICC diagnosis was confirmed by tumor biopsy, surgery or autopsy except in two patients, who were diagnosed by computed tomography or hepatic angiography. The underlying liver disease was liver cirrhosis in six patients and chronic liver disease including mild hepatic fibrosis in four patients. The treatment of liver cancers consisted of surgery, radio-frequency ablation (RFA), transcatheter arterial embolization and transcatheter arterial infusion. Although the follow-up period was relatively short (median 27.5 months, average 32.1 months), all postoperative and post-RFA patients have not had a recurrence of HCC to date, except for one patient who had a palliative operation with intra-arterial infusion of anticancer drugs through an implanted reservoir port. Older age and liver cirrhosis are considered risk factors for HCC in NASH, and regular screening of these patients is necessary. Diabetes may contribute to the development of ICC in NASH. Curative therapy (surgery or RFA) and weight loss by the active therapeutic intervention (nutritional care and exercise therapy) after curative therapy may help us improve the prognosis of HCC in NASH. SN - 0954-691X UR - https://www.unboundmedicine.com/medline/citation/17873605/Primary_liver_cancers_with_nonalcoholic_steatohepatitis_ L2 - https://doi.org/10.1097/MEG.0b013e3282748ef2 DB - PRIME DP - Unbound Medicine ER -